A Phase 2 interventional study of axitinib and axitinib in Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 65 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 29 in phase 2, and was the 3rd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Stephanie Berg · Sites in United States
Ages 18+
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–80
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 213 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 41 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Carcinoma, Renal Cell by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 74 finished, 54 (73%) have results posted.
Among the 80 studies in Carcinoma, Renal Cell by Pfizer, this one is the 9th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2009, is one of 11 in phase 2, and was the 23rd registered.
Pfizer’s Carcinoma, Renal Cell studies by the year they started, since 2002.
2 of the studies testing axitinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07159191Peking Union Medical College HospitalEnvafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | 2027-02-20 |
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, from their registry updates:
Among Pfizer’s 80 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized arm
Drug: axitinib
Randomized arm
Drug: axitinib
Non-randomized arm
Drug: axitinib
Objective Response Rate (ORR) - Percentage of Participants With Objective Response
ORR was defined as the proportion of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Progression-Free Survival (PFS)
The time from first dose administration to first documentation of objective tumor progression or to death due to any cause. PFS in each arm was assessed using the Kaplan-Meier method and estimates of the PFS curves from the Kaplan-Meier method were presented.
Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Duration of Response (DR)
DR was defined as the time from the first documentation of objective tumor response (complete response - CR or Partial response - PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. The median values were estimated based on Kaplan-Meier method. 95% confidence interval was based on the Brookmeyer and Crowley method.
Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks
Overall Survival (OS)
OS was defined as the time from date of the first dose of the study medication to date of death due to any cause. For participants who did not die, their survival times were to be censored at the last date they were known to be alive.
Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Maximum Observed Plasma Concentration (Cmax) of Axitinib
Cmax for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
Time frame: Cycle 2 Day 15 (C2D15): pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib,
Tmax for steady-state axitinib was evaluated on Cycle 2 Day 15.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib
Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Area Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib
Area under the plasma concentration time-curve from zero 24 hours\[AUC(0-24). AUC(0-24) for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Plasma Decay Half-Life (t1/2) for Axitinib
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for steady-state axitinib was evaluated on Cycle 2 Day 15.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Apparent Oral Clearance (CL/F) of Axitinib
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for steady-state axitinib was evaluated on Cycle 2 Day 15.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Apparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for steady-state axitinb was evaluated on Cycle 2 Day 15.
Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Change From Baseline in Systolic Blood Pressure
Value at respective visit minus value at baseline
Time frame: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
Change From Baseline in Diastolic Blood Pressure
Value at respective visit minus value at baseline.
Time frame: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
Comparison of Circulating Endothelial Cells (CECs) in Blood: Cluster of Differentiation (CD)146+/CD105+ at Baseline
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ mean fluorescence intensity (MFI) platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-Vascular endothelial growth factor receptor (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Comparison of the Ratio of CECs in Blood: CD146+/CD105+ at Each Time Point to Baseline
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ MFI platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-VEGFR (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
Time frame: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
Circulating Endothelial Cells (CECs) in Blood: CD31+/CD146+
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Comparison of Ratio of CECs in Blood: CD31+/CD146+ at Each Time Point to Baseline
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
Time frame: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
ORR in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms
ORR, defined as proportion of participants with CR or PR according to RECIST, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms.
Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
PFS in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms
PFS, defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. Estimates of the PFS curves from the Kaplan-Meier method were presented.
Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
This study was conducted at 49 centers in Czech Republic, Germany, Japan, Russian Federation, Spain, and the United States (US).
| Milestone | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization |
|---|---|---|---|---|
| Started | 56 | 56 | 91 | 10 |
| Treated | 56 | 56 | 91 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 56 | 56 | 91 | 10 |
| Withdrew: Death | 33 | 40 | 49 | 4 |
| Withdrew: Lost to follow-up | 3 | 4 | 2 | 1 |
| Withdrew: Other | 5 | 1 | 8 | 0 |
| Withdrew: Objective progression or relapse | 2 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 5 |
| Withdrew: Study terminated by sponsor | 12 | 8 | 30 | 0 |
ORR was defined as the proportion of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.
| Percentage of Participants | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | All Participants |
|---|---|---|---|---|
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response | 53.6 (39.7 to 67.0) | 33.9 (21.8 to 47.8) | 59.3 (48.5 to 69.5) | 48.4 (41.5 to 55.3) |
The time from first dose administration to first documentation of objective tumor progression or to death due to any cause. PFS in each arm was assessed using the Kaplan-Meier method and estimates of the PFS curves from the Kaplan-Meier method were presented.
| Months | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | All Participants |
|---|---|---|---|---|
| Progression-Free Survival (PFS) | 14.5 (9.2 to 24.5) | 15.7 (8.3 to 19.4) | 16.6 (11.2 to 22.5) | 14.6 (11.5 to 17.5) |
DR was defined as the time from the first documentation of objective tumor response (complete response - CR or Partial response - PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. The median values were estimated based on Kaplan-Meier method. 95% confidence interval was based on the Brookmeyer and Crowley method.
| Months | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| Duration of Response (DR) | NA (10.8 to NA) | 21.2 (11.1 to 25.8) | 23.3 (15.7 to 28.6) |
OS was defined as the time from date of the first dose of the study medication to date of death due to any cause. For participants who did not die, their survival times were to be censored at the last date they were known to be alive.
| Months | Active Titration Arm (FA Population) | Placebo Titration Arm (FA Population) | Non-randomized Arm (SA Population) |
|---|---|---|---|
| Overall Survival (OS) | 42.7 (24.7 to NA) | 30.4 (23.7 to 45.0) | 41.6 (33.0 to NA) |
Cmax for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
| ng/mL | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Axitinib | 31.74 (21.63 to 46.58) | 23.05 (16.36 to 32.49) |
Tmax for steady-state axitinib was evaluated on Cycle 2 Day 15.
| hrs | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, | 2.04 (1.00 to 6.00) | 2.00 (0.00 to 6.00) |
Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
| ng.hr/mL | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib | 105.33 (70.16 to 158.14) | 78.44 (54.53 to 112.82) |
Area under the plasma concentration time-curve from zero 24 hours\[AUC(0-24). AUC(0-24) for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.
| ng.hr/mL | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Area Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib | 258.68 (150.47 to 444.72) | 161.38 (102.09 to 255.12) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for steady-state axitinib was evaluated on Cycle 2 Day 15.
| hr | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Plasma Decay Half-Life (t1/2) for Axitinib | 2.48 ± 1.902 | 2.81 ± 1.685 |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for steady-state axitinib was evaluated on Cycle 2 Day 15.
| L/hr | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Apparent Oral Clearance (CL/F) of Axitinib | 54.15 (31.49 to 93.12) | 61.93 (39.17 to 97.91) |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for steady-state axitinb was evaluated on Cycle 2 Day 15.
| L | Active Titration Arm | Placebo Titration Arm |
|---|---|---|
| Apparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib | 158.18 (98.38 to 254.34) | 216.62 (145.00 to 323.60) |
Value at respective visit minus value at baseline
| mmHg | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| Cycle 1 Day 1 (n=52,51,73) | -4.3 ± 11.1 | -2.9 ± 9.2 | -1.8 ± 14.2 |
| Cycle 1 Day 15 (n=56,56,91) | 3.8 ± 12.2 | 4.1 ± 12.5 | 11.5 ± 18.0 |
| Cycle 2 Day 1 (n=56,56,91) | 1.9 ± 12.4 | 0.9 ± 13.6 | 9.9 ± 18.7 |
| Cycle 2 Day 15 (n=55,55,86) | 3.6 ± 13.8 | 2.7 ± 16.6 | 5.9 ± 20.3 |
| Cycle 3 Day 1 (n=48,49,84) | 3.5 ± 15.1 | 8.4 ± 15.4 | 5.2 ± 20.2 |
| Cycle 4 Day 1 (n=45,48,79) | 4.3 ± 12.7 | 3.5 ± 13.0 | 5.5 ± 18.2 |
| End of treatment (n=35,44,51) | 2.4 ± 17.0 | 1.7 ± 14.0 | -2.8 ± 19.0 |
| Follow-up (n=16,25,36) | -3.6 ± 16.9 | -0.4 ± 16.3 | -0.6 ± 16.7 |
Value at respective visit minus value at baseline.
| mmHg | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| Cycle 1 Day 1 (n=52,51,73) | -1.6 ± 8.2 | -2.6 ± 7.4 | 0.5 ± 8.4 |
| Cycle 1 Day 15 (n=56,56,91) | 4.8 ± 8.5 | 3.0 ± 7.7 | 11.5 ± 10.0 |
| Cycle 2 Day 1 (n=56,56,91) | 4.2 ± 9.0 | 3.5 ± 8.0 | 10.5 ± 10.5 |
| Cycle 2 Day 15 (n=55,55,86) | 5.5 ± 10.5 | 4.4 ± 10.7 | 9.7 ± 11.3 |
| Cycle 3 Day 1 (n=48,49,84) | 6.6 ± 8.3 | 5.9 ± 9.3 | 9.1 ± 13.6 |
| Cycle 4 Day 1 (n=45,48,79) | 7.4 ± 8.2 | 4.6 ± 8.5 | 8.7 ± 11.8 |
| End of treatment (n=35,44,51) | 0.6 ± 10.8 | 3.5 ± 6.3 | 3.0 ± 10.5 |
| Follow-up (n=16,25,36) | -4.5 ± 10.1 | -1.3 ± 8.5 | 1.8 ± 9.0 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ mean fluorescence intensity (MFI) platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-Vascular endothelial growth factor receptor (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
| Fluorescent Intensity Unit (FIU) | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| Baseline CECs Count (n=17,22,20) | 23584 ± 18213.1 | 28544 ± 27694.4 | 29663 ± 30651.0 |
| Baseline MFI PDGFR-BETA (n=17,22,20) | 346815 ± 179563 | 455238 ± 238157 | 327567 ± 167728 |
| Baseline MFI pPDGFR-BETA (n=17,22,20) | 401226 ± 195445 | 395509 ± 136933 | 397672 ± 193172 |
| Baseline MFI pVEGFR (n=16,22,20) | 456086 ± 290174 | 436197 ± 128225 | 398754 ± 188137 |
| Baseline MFI VEGFR (n=16,22,20) | 367799 ± 181320 | 473290 ± 228619 | 359092 ± 167706 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ MFI platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-VEGFR (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
| Ratio | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| C1D15:C1D1 CECs Count (n=11,18,14) | 2.3 ± 2.52 | 3.7 ± 6.92 | 2.2 ± 3.10 |
| C2D15:C1D1 CECs Count (n=13,16,11) | 1.3 ± 1.43 | 4.4 ± 9.27 | 1.3 ± 1.22 |
| EOT:C1D1 CECs Count (n=7,9,4) | 2.8 ± 4.81 | 8.9 ± 21.70 | 1.2 ± 1.50 |
| C1D15:C1D1 MFI PDGFRBETA (n=11,17,13) | 1.3 ± 1.03 | 1.5 ± 1.14 | 1.1 ± 0.73 |
| C2D15:C1D1 MFI PDGFRBETA (n=13,16,11) | 1.4 ± 1.24 | 1.1 ± 1.14 | 2.2 ± 1.62 |
| EOT:C1D1 MFI PDGFRBETA (n=7,9,4) | 1.5 ± 1.75 | 0.6 ± 0.52 | 1.2 ± 1.78 |
| C1D15:C1D1 MFI pPDGFR-BETA (n=11,17,13) | 1.1 ± 0.63 | 1.2 ± 0.77 | 1.0 ± 1.12 |
| C2D15:C1D1 MFI pPDGFR-BETA (n=13,16,11) | 1.0 ± 0.69 | 0.8 ± 0.45 | 1.2 ± 0.79 |
| EOT:C1D1 MFI pPDGFRBETA (n=7,9,4) | 0.8 ± 0.71 | 0.8 ± 0.93 | 1.9 ± 1.57 |
| C1D15:C1D1 MFI pVEGFR (n=10,18,14) | 1.0 ± 0.46 | 1.2 ± 0.88 | 1.2 ± 1.00 |
| C2D15:C1D1 MFI pVEGFR (n=12,16,11) | 1.0 ± 0.74 | 0.9 ± 0.82 | 1.2 ± 0.80 |
| EOT:C1D1 MFI pVEGFR (n=7,9,4) | 0.8 ± 0.53 | 1.3 ± 0.96 | 3.0 ± 1.16 |
| C1D15:C1D1 MFI VEGFR (n=10,18,14) | 1.4 ± 1.25 | 1.3 ± 0.94 | 1.0 ± 0.64 |
| C2D15:C1D1 MFI VEGFR (n=12,16,11) | 1.5 ± 1.48 | 1.3 ± 0.99 | 2.1 ± 1.72 |
| EOT:C1D1 MFI VEGFR (n=7,9,4) | 1.1 ± 1.03 | 0.7 ± 0.48 | 1.9 ± 1.63 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
| Fluorescent Intensity Unit (FIU) | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| Baseline CECs Count (n=17,22,20) | 74668 ± 50558.9 | 76258 ± 46779.5 | 77437 ± 63419.4 |
| Baseline MFI PDGFR-BETA (n=17,21,20) | 333760 ± 164604 | 380886 ± 147261 | 442642 ± 267436 |
| Baseline MFI pPDGFR-BETA (n=17,21,20) | 380139 ± 205600 | 355441 ± 147046 | 383202 ± 211174 |
| Baseline MFI pVEGFR (n=17,22,20) | 385617 ± 203956 | 352644 ± 128803 | 380184 ± 173578 |
| Baseline MFI VEGFR (n=17,22,20) | 330333 ± 151710 | 401909 ± 165235 | 359097 ± 146943 |
CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.
| Ratio | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| C1D15:C1D1 CECs Count (n=11,18,14) | 2.7 ± 3.17 | 1.6 ± 2.32 | 1.5 ± 2.31 |
| C2D15:C1D1 CECs Count (n=13,16,11) | 1.4 ± 1.38 | 2.2 ± 3.91 | 2.5 ± 3.98 |
| EOT:C1D1 CECs COUNT (n=7,9,4) | 1.5 ± 1.95 | 1.4 ± 2.66 | 0.6 ± 0.71 |
| C1D15:C1D1 MFI PDGFRBETA (n=11,15,13) | 1.2 ± 0.74 | 1.3 ± 0.89 | 0.8 ± 0.51 |
| C2D15:C1D1 MFI PDGFRBETA (n=13,14,11) | 1.4 ± 1.36 | 1.1 ± 1.03 | 2.2 ± 2.64 |
| EOT:C1D1 MFI PDGFRBETA (n=6,8,4) | 1.2 ± 1.23 | 0.6 ± 0.51 | 1.7 ± 1.49 |
| C1D15:C1D1 MFI pPDGFR-BETA (n=11,15,13) | 1.2 ± 1.07 | 1.4 ± 0.81 | 1.0 ± 0.87 |
| C2D15:C1D1 MFI pPDGFR-BETA (n=13,14,11) | 1.2 ± 0.89 | 0.8 ± 0.38 | 1.1 ± 0.71 |
| EOT:C1D1 MFI pPDGFRBETA (n=6,8,4) | 0.7 ± 0.63 | 0.8 ± 0.91 | 3.0 ± 0.47 |
| C1D15:C1D1 MFI pVEGFR (n=11,18,14) | 1.1 ± 0.75 | 1.4 ± 0.74 | 1.2 ± 0.90 |
| C2D15:C1D1 MFI pVEGFR (n=13,16,10) | 1.2 ± 1.00 | 0.9 ± 0.68 | 1.3 ± 0.70 |
| EOT:C1D1 MFI pVEGFR (n=7,9,4) | 0.7 ± 0.59 | 1.1 ± 1.24 | 3.1 ± 0.95 |
| C1D15:C1D1 MFI VEGFR (n=11,18,14) | 1.3 ± 0.93 | 1.3 ± 0.90 | 1.0 ± 0.57 |
| C2D15:C1D1 MFI VEGFR n=13,16,10) | 1.5 ± 1.44 | 1.2 ± 0.96 | 2.1 ± 1.80 |
| EOT:C1D1 MFI VEGFR (n=7,9,4) | 1.2 ± 1.27 | 1.1 ± 0.90 | 1.5 ± 1.42 |
ORR, defined as proportion of participants with CR or PR according to RECIST, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms.
| Percentage of participants | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14) | 85.7 (42.1 to 99.6) | 22.2 (2.8 to 60.0) | 42.9 (17.7 to 71.1) |
| VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41) | 54.5 (32.2 to 75.6) | 35.0 (15.4 to 59.2) | 65.9 (49.4 to 79.9) |
| VEGFA/rs699947 Genotype: C/C (n = 14, 14, 24) | 50.0 (23.0 to 77.0) | 35.7 (12.8 to 64.9) | 66.7 (44.7 to 84.4) |
| VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43) | 59.1 (36.4 to 79.3) | 39.1 (19.7 to 61.5) | 67.4 (51.5 to 80.9) |
| VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29) | 57.9 (33.5 to 79.7) | 18.8 (4.0 to 45.6) | 58.6 (38.9 to 76.5) |
| VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 7) | 50.0 (1.3 to 98.7) | 50.0 (6.8 to 93.2) | 42.9 (9.9 to 81.6) |
| VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28) | 81.3 (54.4 to 96.0) | 53.3 (26.6 to 78.7) | 60.7 (40.6 to 78.5) |
| VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35) | 45.5 (24.4 to 67.8) | 18.2 (5.2 to 40.3) | 57.1 (39.4 to 73.7) |
| VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16) | 40.0 (5.3 to 85.3) | 33.3 (4.3 to 77.7) | 75.0 (47.6 to 92.7) |
| VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 79) | 58.3 (40.8 to 74.5) | 30.8 (17.0 to 47.6) | 64.3 (51.9 to 75.4) |
| VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9) | 50.0 (11.8 to 88.2) | 50.0 (6.8 to 93.2) | 44.4 (13.7 to 78.8) |
| VEGFR3/rs307826 Genotype: G/G (n = 1, 0, 0) | 100.0 (2.5 to 100.0) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
| VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 79) | 55.6 (38.1 to 72.1) | 28.9 (15.4 to 45.9) | 65.2 (52.8 to 76.3) |
| VEGFR3/rs307821 Genotype: G/T (n = 6, 5, 10) | 66.7 (22.3 to 95.7) | 60.0 (14.7 to 94.7) | 40.0 (12.2 to 73.8) |
| VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0) | 100.0 (2.5 to 100.0) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
PFS, defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. Estimates of the PFS curves from the Kaplan-Meier method were presented.
| Months | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm |
|---|---|---|---|
| VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14) | NA (1.74 to NA) | 11.50 (3.58 to NA) | 7.33 (5.06 to 13.83) |
| VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41) | 11.07 (3.02 to 17.44) | 9.67 (1.91 to 16.59) | 16.59 (10.97 to NA) |
| VEGFA/rs699947 Genotype: C/C (n = 14, 14, 41) | 18.74 (1.84 to NA) | 24.64 (4.01 to NA) | 25.13 (8.28 to 30.45) |
| VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43) | 14.62 (7.39 to NA) | 19.42 (5.81 to 27.63) | 25.13 (11.47 to 30.45) |
| VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29) | 12.78 (1.84 to NA) | 8.34 (1.91 to 16.59) | 13.90 (8.28 to 22.54) |
| VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 29) | NA (1.74 to NA) | 10.04 (3.58 to NA) | 8.57 (1.74 to NA) |
| VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28) | 17.44 (12.78 to NA) | 19.42 (5.35 to NA) | 22.54 (8.08 to NA) |
| VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35) | 9.18 (1.84 to NA) | 8.31 (3.58 to 16.52) | 13.83 (5.62 to 16.59) |
| VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16) | 11.07 (1.84 to NA) | 15.67 (1.91 to 27.63) | NA (8.57 to NA) |
| VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 70) | 13.73 (8.28 to 24.47) | 15.67 (8.21 to 22.17) | 16.56 (10.28 to 25.13) |
| VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9) | 16.52 (1.18 to NA) | 7.93 (1.84 to 11.86) | 16.26 (2.66 to 30.45) |
| VEGFR3/rs307826 Genotype: G/G (n = 0, 0, 0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 69) | 12.78 (7.39 to 24.47) | 15.67 (8.21 to 23.95) | 16.59 (10.28 to 28.52) |
| VEGFR3/rs307821 Genotype: G/T (n = 36, 38, 10) | 24.80 (1.18 to NA) | 8.34 (1.84 to 11.86) | 13.86 (2.66 to 30.45) |
| VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over AEs were reported until follow up visit. Non-SAEs: up to 28 days post last dose or upon starting new anticancer treatment, whichever was first. SAEs: up to 28 days post last dose, irrespective of new anticancer treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Titration Arm | — | 25/56 (44.6%) | 55/56 (98.2%) |
| Placebo Titration Arm | — | 14/56 (25%) | 51/56 (91.1%) |
| Non-randomized Arm | — | 39/91 (42.9%) | 91/91 (100%) |
| Discontinued Prior to Randomization | — | 2/10 (20%) | 9/10 (90%) |
| Event | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 5/56 | 0/56 | 3/91 | 1/10 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/56 | 0/56 | 0/91 | 1/10 |
| Renal failureRenal and urinary disorders | 0/56 | 0/56 | 0/91 | 1/10 |
| Hypertensive crisisVascular disorders | 0/56 | 0/56 | 0/91 | 1/10 |
| Myocardial infarctionCardiac disorders | 4/56 | 0/56 | 2/91 | 0/10 |
| Disease progressionGeneral disorders | 1/56 | 1/56 | 6/91 | 0/10 |
| VomitingGastrointestinal disorders | 3/56 | 1/56 | 1/91 | 0/10 |
| PneumoniaInfections and infestations | 3/56 | 2/56 | 1/91 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 2/56 | 1/56 | 1/91 | 0/10 |
| NauseaGastrointestinal disorders | 2/56 | 0/56 | 0/91 | 0/10 |
| Event | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization |
|---|---|---|---|---|
| HypertensionVascular disorders | 35/56 | 24/56 | 76/91 | 5/10 |
| DiarrhoeaGastrointestinal disorders | 34/56 | 35/56 | 58/91 | 1/10 |
| FatigueGeneral disorders | 27/56 | 26/56 | 49/91 | 4/10 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 18/56 | 20/56 | 44/91 | 3/10 |
| HypothyroidismEndocrine disorders | 18/56 | 13/56 | 41/91 | 2/10 |
| ProteinuriaRenal and urinary disorders | 12/56 | 12/56 | 40/91 | 2/10 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 18/56 | 10/56 | 40/91 | 0/10 |
| NauseaGastrointestinal disorders | 24/56 | 19/56 | 33/91 | 2/10 |
| Decreased appetiteMetabolism and nutrition disorders | 21/56 | 16/56 | 37/91 | 3/10 |
| VomitingGastrointestinal disorders | 18/56 | 12/56 | 25/91 | 2/10 |
The safety analysis (SA) population consists of all participants who received at least one dose of study medication.
| Age, Continuous(Years) | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization | Total |
|---|---|---|---|---|---|
| Mean | 59.7 ± 10.2 | 59.6 ± 10.5 | 62.9 ± 8.9 | 62.9 ± 7.5 | 61.2 ± 9.7 |
| Age, Customized(Participants) | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization | Total |
|---|---|---|---|---|---|
| < 65 Years | 38 | 38 | 54 | 6 | 136 |
| >= 65 Years | 18 | 18 | 37 | 4 | 77 |
| Sex: Female, Male(Participants) | Active Titration Arm | Placebo Titration Arm | Non-randomized Arm | Discontinued Prior to Randomization | Total |
|---|---|---|---|---|---|
| Female | 19 | 11 | 36 | 4 | 70 |
| Male | 37 | 45 | 55 | 6 | 143 |
The record gives a start of Aug 2009, a primary completion of Oct 2012 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib